Clinical Trial Update: POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on POSLUMA (18F-rhPSMA-7.3) PET-CT for evaluating PIRADS 2/3 lesions in prostate cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• POSLUMA (FLOTUFOLASTAT F-18)

Snippet

Sponsor: University of Florida | Conditions: Prostate | Phase 2 | Status: RECRUITING